Letter to the Editor
- Page Path
-
- HOME
- ARTICLE CATEGORY
- Letter to the Editor
- Letter to the Editor
- Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
- Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
- Clin Mol Hepatol. 2025;31(2):e145-e148. Published online October 29, 2024
-
View: 1135 Download: 77
- Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
- Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang
- Clin Mol Hepatol. 2025;31(2):e140-e142. Published online December 3, 2024
-
View: 787 Download: 27 Crossref: 1
- Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatitis B in China”
- Chunlong Liu, Jiangtao Yu
- Clin Mol Hepatol. 2025;31(2):e134-e136. Published online December 17, 2024
-
View: 1021 Download: 83
- Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
- Hai Xu, Yong Zhou, Huikun Wu
- Clin Mol Hepatol. 2025;31(2):e125-e127. Published online December 17, 2024
-
View: 911 Download: 30 Crossref: 1
- MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
- Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
- Clin Mol Hepatol. 2025;31(2):e128-e133. Published online December 26, 2024
-
View: 1203 Download: 74 Crossref: 2
- Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
- Rui Shi, Minghua Wang
- Clin Mol Hepatol. 2025;31(2):e137-e139. Published online January 9, 2025
-
View: 725 Download: 41 Crossref: 1
- Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
- Wei Wang, Yating Xie, Ailei Xu
- Clin Mol Hepatol. 2025;31(2):e143-e144. Published online February 18, 2025
-
View: 644 Download: 34
- Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
- Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang
- Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024
-
View: 1122 Download: 52 Crossref: 1
- Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau
- Clin Mol Hepatol. 2025;31(1):e13-e14. Published online September 2, 2024
-
View: 1289 Download: 103 Crossref: 1
- Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
- Xiao-Song Li, Xi-Ping Shen, Hang Li
- Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024
-
View: 1022 Download: 42 Web of Science: 1 Crossref: 1
- Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
- Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
- Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024
-
View: 1204 Download: 67 Web of Science: 1 Crossref: 1
- Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
- Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
- Clin Mol Hepatol. 2025;31(1):e31-e34. Published online September 20, 2024
-
View: 1283 Download: 109 Crossref: 2
- Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening
- Jiawen Wang, Tian Xia
- Clin Mol Hepatol. 2025;31(1):e1-e2. Published online September 26, 2024
-
View: 984 Download: 49
- Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
- Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li
- Clin Mol Hepatol. 2025;31(1):e3-e4. Published online October 7, 2024
-
View: 1050 Download: 50 Crossref: 1
- Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
- Donghee Kim, Won Kim, Aijaz Ahmed
- Clin Mol Hepatol. 2025;31(1):e5-e7. Published online October 8, 2024
-
View: 992 Download: 41 Crossref: 1
- Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma
- Xiping Shen, Ji Wu
- Clin Mol Hepatol. 2025;31(1):e17-e18. Published online October 11, 2024
-
View: 1100 Download: 48 Crossref: 1
- Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
- Wei Feng, Qile Wang, Qingwang Ye
- Clin Mol Hepatol. 2025;31(1):e21-e22. Published online October 11, 2024
-
View: 1101 Download: 28
- Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs
- Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
- Clin Mol Hepatol. 2025;31(1):e19-e20. Published online October 17, 2024
-
View: 913 Download: 33
- Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China
- Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang
- Clin Mol Hepatol. 2025;31(1):e39-e43. Published online October 23, 2024
-
View: 964 Download: 57 Crossref: 1
- Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models
- Zhanna Zhang, Gongqiang Wu
- Clin Mol Hepatol. 2025;31(1):e8-e9. Published online November 6, 2024
-
View: 945 Download: 40 Web of Science: 1 Crossref: 1
- Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance
- Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu
- Clin Mol Hepatol. 2025;31(1):e10-e12. Published online November 26, 2024
-
View: 1350 Download: 60
- Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus
- Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng
- Clin Mol Hepatol. 2025;31(1):e23-e24. Published online November 26, 2024
-
View: 830 Download: 23
- The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
- Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang
- Clin Mol Hepatol. 2025;31(1):e25-e26. Published online December 10, 2024
-
View: 968 Download: 40 Crossref: 1
- Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
- Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
- Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024
-
View: 1808 Download: 66 Web of Science: 1 Crossref: 1
- Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
- Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau
- Clin Mol Hepatol. 2024;30(4):978-981. Published online August 5, 2024
-
View: 1567 Download: 56 Web of Science: 1 Crossref: 2
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
- Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li
- Clin Mol Hepatol. 2024;30(4):974-977. Published online July 4, 2024
-
View: 1982 Download: 81 Crossref: 1
- Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
- Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip
- Clin Mol Hepatol. 2024;30(4):970-973. Published online July 4, 2024
-
View: 1775 Download: 62 Web of Science: 1 Crossref: 1
- Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
- Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li
- Clin Mol Hepatol. 2024;30(4):965-969. Published online June 18, 2024
-
View: 2318 Download: 91
- Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
- Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024
-
View: 2032 Download: 107 Web of Science: 2 Crossref: 4
- Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia
- Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi
- Clin Mol Hepatol. 2024;30(4):959-961. Published online May 10, 2024
-
View: 1844 Download: 72 Web of Science: 5 Crossref: 5
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
Video abstract
-
- Modulation of lymphatic vessels in management of liver disease and complications
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
- Examining the therapeutic landscape of beta-blockers in portal hypertension
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor14.0First decision
07 Days
Publication after acceptance
04 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2023-2025)
|
|||||||
